Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB has been granted a new patent in the US for the salt form of its drug candidate mesdopetam, which is aimed at treating levodopa-induced dyskinesias in Parkinson’s disease patients. This patent extends the company’s market exclusivity into the 2040s, enhancing the value of mesdopetam and reinforcing IRLAB’s position in the Parkinson’s treatment market.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing transformative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research group, the company is known for its innovative approach to addressing brain neurotransmitter disorders. Its pipeline includes mesdopetam, pirepemat, and IRL757, among others, with several candidates in various stages of clinical development.
Average Trading Volume: 86,916
Current Market Cap: SEK378.1M
For an in-depth examination of IRLAB.A stock, go to TipRanks’ Stock Analysis page.